company profile of SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.，Contact Information for SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.

Recommended Products

Calcium 3-methyl-2-oxobutyrate

Phenylpyruvic acid calcium salt

Calcium bis(2-hydroxy-4-(methylthio)butyrate)

Nifuratel

2-Propen-1-amine polymer with (chloromethyl)oxirane carbonate

Erlotinib hydrochloride intermediate

Chloropretadalafil

Intermediates of sorafenib tosylate

Sunitinib malate intermediates

diimidazole

Calcium ketoate intermediates

Febuxostat intermediates

Rosuvastatin calcium intermediate

Calcium phenylpyruvate

Calcium α-ketovaline

Calcium 3-Methyl-2-oxovalerate

4-Methyl-2-oxovaleric acid calcium

Dithiothreitol

2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)benzimidazole

Calcium bis(2-hydroxy-4-(methylthio)butyrate);

Amprolium Hydrochloride

Tadalafil

Sorafenib Tosylate

Febuxostat

Telmisartan

Policresulen

Erlotinib Hydrochloride

Rosuvastatin Calcium

Sunitinib Malate

Categories

Contact Supplier

From:
To:
SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.
Send a Copy to this Email
Message:
Upload Images / Files
- Supports jpg, jpeg, png,
gif, pdf, doc, docx,
xls, xlsx, txt, rar and zip
- Max upload 3 files;
Max total size: 3MB
(0/3)
Verification:

Previous page 1 2 3 Next page

Company Profile

Shandong Fengjin Pharmaceutical Co., Ltd.(herein after as Fengjin Pharmaceutical), a wholly-owned subsidiary invested by Shandong Fengjin Bio-pharmaceutical Co., Ltd., is mainly engaged in the research and development, production and sales of chemical APIs. Fengjin Pharmaceutical was founded in March 2019 with registered capital of 66 million RMB. The project is located at No. 777 of Jinniushan Road, Wuning subdistrict-office, Muping District, Yantai City, with a total investment of 620 million RMB, covering a total area of 180,000 square meters which is divided into three phases of construction. The first phase of the project covers an area of 53,333 square meters and construction area of 40,000 square meters with an investment of 220 million RMB. The construction of the project started in February 2020 and the main construction has been completed at present. It is expected to be completed in June 2023 and officially put into production in July 2023.Active ingredients: febuxostat, Rosuvastatin calcium, Ranvastinib mesylate, Sunitinib malate, Sorafenib toluenesulfonate, erotinib hydrochloride, tadalafil, telmisartan, calcium ketoate, polycresol sulfonal. Animal drug: aminopropyl hydrochloride. Intermediates and chemicals: diimidazole, dithiothreitol

more >

Our Company Our Business

Year of Establishment: 2019

Total Assets(USD): More than 99,999,999

Total Number of Staff: 50-100

Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service

Other Competitive Advantages:

Patents and Copyrights:

Send Inquiry View More

SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.
Contact Person : Tan Xiaohui
Tel : Click to View
Fax : --

Send your message to this supplier

From:
To:
SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.
Send a Copy to this Email
Message:
Upload Images / Files
- Supports jpg, jpeg, png,
gif, pdf, doc, docx,
xls, xlsx, txt, rar and zip
- Max upload 3 files;
Max total size: 3MB
(0/3)

Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now
Verification: